Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Pulse Therapy & Lupus Nephritis: A 40-Year History, 1976–2016

Morton Scheinberg, MD, PhD  |  January 17, 2017

Corticosteroids still represent the mainstay of treatment of patients with active disease. They have been used for more than 60 years, and although prolonged use is associated with organ damage, they have been shown to be lifesaving in various phases of the history of the disease. History of Use First introduced in the late 1960s…

Filed under:ConditionsOther Rheumatic Conditions

Do Fevers Offer Insight into Diagnosis & Disease?

Karen Appold  |  January 17, 2017

Patients experience fevers for many reasons, but can they help physicians diagnose disease? Using modern technology and social media, Jonathan S. Hausmann, MD, is working to further the understanding of body temperatures…

Filed under:ConditionsResearch Rheum Tagged with:feverResearchSocial Media

Stronger Malpractice Laws May Not Prevent Surgical Complications

Lisa Rapaport  |  January 15, 2017

(Reuters Health)—More aggressive malpractice climates don’t necessarily protect patients from surgical complications, a new study suggests. Supporters of medical malpractice laws that make it easier for patients to sue doctors say these protections are necessary to improve care. But in the current study, the risk of litigation didn’t translate into better outcomes, said study leader…

Filed under:Legal UpdatesProfessional Topics Tagged with:LegalmalpracticeMedical MalpracticeMedicaresurgerysurgical procedure

Pfizer Announces Medicare Reimbursement for Inflectra (infliximab-dyyb), the First Biosimilar Monoclonal Antibody Available in the United States

Pfizer  |  January 13, 2017

On Jan. 6, Pfizer Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has included payment information for INFLECTRA (infliximab-dyyb), a biosimilar to REMICADE (infliximab), in its January Average Selling Price (ASP) pricing file. This pricing took effect as of January 1, 2017. Additional claims processing information is listed in the MLN Matters…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biologics & BiosimilarsCenters for Medicare & Medicaid Services (CMS)InflectraINFLECTRA (infliximab-dyyb)Pfizer Inc.REMICADE (infliximab)

Guselkumab Improves Active Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP, & Lara C. Pullen, PhD  |  January 11, 2017

A study showed that guselkumab may decrease symptoms of psoriatic arthritis and improve quality of life in adult patients…

Filed under:Biologics/DMARDsDrug Updates

Insurance Subcommittee to the Rescue

Mary Beth Nierengarten  |  January 4, 2017

Concerned about reimbursement for specialty drugs? Wondering if your patient can continue on a prescribed medication despite formulary changes? Unsure how to request a tier exception? No need to face these issues alone. The ACR has a resource that can assist with questions regarding coverage and payment policies for private insurers and Medicare. That resource…

Filed under:Practice SupportProfessional TopicsQuality Assurance/Improvement Tagged with:ACR Insurance Subcommitteedowncodinginsurance advocacyinsurance coverageMedicarepayment policies

FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling

Michele B. Kaufman, PharmD, BCGP  |  January 4, 2017

The makers of FX006, a steroid injection for treating pain in patients with knee osteoarthritis, have submitted a new drug application to the FDA…

Filed under:AnalgesicsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:CancerFDAFood and Drug AdministrationFX006HIVkneeKnee Osteoarthritis (OA)Painpioglitazone

Liquid Biopsy Provides Insights into Lupus

Lara C. Pullen, PhD  |  January 2, 2017

Microparticles in the blood of SLE patients may be a source of extracellular HMGB1, which is involved in immune response. Researchers found that analysis may be able to determine if the patient is producing dead, dying and activated cells that are important for SLE pathogenesis…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:biopsyLupusmicroparticlessystemic lupus erythematosus (SLE)Test

New Test Yields Rapid Infliximab Drug Concentrations

Will Boggs, MD  |  December 22, 2016

NEW YORK (Reuters Health)—A new test provides rapid infliximab drug concentrations that enable immediate dosing adjustments, researchers from Belgium report. “With this rapid test, our biggest wish is to persuade physicians to now perform and use infliximab measurements also in their own daily clinical practice, as many practical and organizational issues that went along with…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biologicsdrug developmentinfliximab

Certolizumab Pegol Usage Compatible with Breastfeeding

Michele B. Kaufman, PharmD, BCGP  |  December 20, 2016

In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…

Filed under:Drug Updates Tagged with:breast milkbreastfeedingCertolizumab Pegolinfantspregnancy

  • « Previous Page
  • 1
  • …
  • 195
  • 196
  • 197
  • 198
  • 199
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences